Summary
Background Parkinson’s disease (PD) is a progressive neurodegenerative disorder. Mendelian forms have revealed multiple genes, with a notable emphasis on membrane trafficking; RAB GTPases play an important role in PD as a subset are both regulators and substrates of LRRK2 protein kinase. To explore the role of RAB GTPases in PD, we undertook a comprehensive examination of their genetic variability in familial PD.
Methods Affected probands from 130 multi-incident PD families underwent whole-exome sequencing and genotyping, Potential pathogenic variants in 61 RAB GTPases were genotyped in relatives to assess disease segregation. These variants were also genotyped in a larger case-control series, totaling 3,078 individuals (2,734 with PD). The single most significant finding was subsequently validated within genetic data (6,043 with PD). Clinical and pathologic findings were summarized for gene-identified patients, and haplotypes were constructed. In parallel, wild-type and mutant RAB GTPase structural variation, protein interactions, and resultant enzyme activities were assessed.
Findings We found RAB32 c.213C>G (Ser71Arg) to co-segregate with autosomal dominant parkinsonism in three multi-incident families. RAB32 Ser71Arg was also significantly associated with PD in case-control samples: genotyping and database searches identified thirteen more patients with the same variant that was absent in unaffected controls. Notably, RAB32 Ser71Arg heterozygotes share a common haplotype. At autopsy, one patient had sparse neurofibrillary tangle pathology in the midbrain and thalamus, without Lewy body pathology. In transfected cells the RAB32 Arg71 was twice as potent as Ser71 wild type to activate LRRK2 kinase.
Interpretation Our study provides unequivocal evidence to implicate RAB32 Ser71Arg in PD. Functional analysis demonstrates LRRK2 kinase activation. We provide a mechanistic explanation to expand and unify the etiopathogenesis of monogenic PD.
Funding National Institutes of Health, the Canada Excellence Research Chairs program, Aligning Science Across Parkinson’s, the Michael J. Fox Foundation for Parkinson’s Research, and the UK Medical Research Council.
Competing Interest Statement
AR receives unrestricted research support from the Dr. Ali Rajput Endowment for Parkinsons Disease and Movement Disorders; in the past two years AR has received honoraria from CQDM/Brain Canada and Ipsen Biopharmaceuticals Canada. MSG reports grants from NIH/NINDS and the Michael J. Fox Foundation for Parkinsons Research. AJS has received fees from Neurocrine (Chair, DSMB), AskBio (Member, DSMB) and Capsida (advisor), receives a stipend from the International Parkinsons and Movement Disorders Society (Editor-in-Chief, Movement Disorders) and grant funding from Michael J. Fox Foundation, Weston Brain Institute and Brain Canada. ZGO received consultancy fees from Bial Biotec, Bial, Capsida, Handl Therapeutics, Idorsia, Neuron23, Ono Therapeutics, Prevail Therapeutics, UCB and Vanqua. He reports grants from the Michael J. Fox Foundation for Parkinsons Research, The Weston Family Foundation, The Silverstein Foundation, NIH and the Canadian Consortium on Neurodegeneration in Aging (CCNA). MJF reports US patents associated with LRRK2 mutations and mouse models (8409809, 8455243), and methods of treating neurodegenerative disease (20110092565). SAC has received honoraria from Merz, and grant funding from the Pacific Parkinsons Research Institute, the Weston Family Foundation, Parkinson Canada, Canadian Institutes of Health Research, the VGH and UBC Hospital Foundation, Ricks Heart Foundation and the Jack and Darlene Poole Foundation.
Funding Statement
Initial studies in Tunisia on familial parkinsonism were in collaboration with Lefkos Middleton, Rachel Gibson, and the GlaxoSmithKline PD Programme Team (2002-2005). Subsequent clinical and molecular genetic analysis were supported through Mayo Foundation, GlaxoSmithKline, and National Institutes of Health (NINDS P50 NS40256; NINDS R21 NS064885; 2005-2009). Molecular, bioinformatics and statistical analysis were funded through the Canada Excellence Research Chairs program, CIHR/IRSC 275675 (2010-2017). We also gratefully acknowledge the Don Rix BC Leadership Chair in Genetic Medicine, and the Lee and Lauren Fixel Chair in Parkinsons disease that supported MJF lab research. Aligning Science Across Parkinsons (ASAP)[Grant number: ASAP-000463], the Michael J. Fox Foundation for Parkinsons Research (MJFF) and the UK Medical Research Council [grant number MC_UU_00018/1], and the pharmaceutical companies supporting the Division of Signal Transduction Therapy Unit (Boehringer Ingelheim, GlaxoSmithKline, Merck KGaA) support DRA lab research. Follow up studies were also supported by ASAP [Grant numbers: ASAP-000478 and ASAP-000509] and MJFF. Data used in the preparation of this article were obtained from Global Parkinsons Genetics Program (GP2). GP2 is also funded by ASAP, implemented by MJFF (https://gp2.org). For a complete list of GP2 members see https://gp2.org. This research was made possible through access to data in the National Genomic Research Library, which is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The National Genomic Research Library holds data provided by patients and collected by the NHS as part of their care and data collected as part of their participation in research. The National Genomic Research Library is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the Research Ethics Board of the University of British Columbia (PI: MJ Farrer, under CAN NDG H10-02191, Clinical, genealogic and genetic studies of Parkinsons disease, CAN PD H10-01461 Neurogenetic studies of Parkinsons disease and related Neurodegenerative syndromes and CAN ARC H11-02030 Clinical genealogic and genetic studies of Parkinson syndrome and related disorders, 2010-2019). From 2019 when Dr. Farrers moved to the University of Florida, and until the present day, this study and its related research ethics have been reviewed and approved by the University of Florida under IRB202000632 Genomic Analysis of Brain Health and Disease and IRB202001661 Biospecimens and associated genomic data bank. These protocols include review and approval of all the research ethics of all collaborative partners. This is with the exception of de-identified data originating from Genome England, AMP-PD and GP2, for which more details can be found on their respective websites.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All GP2 data are hosted in collaboration with the Accelerating Medicines Partnership in Parkinsons Disease and are available via application on the website. All Genomics England data are hosted in a cloud workspace called the Research Environment. To access the data, researchers must first apply to become a member of either the Genomics England Clinical Interpretation Partnership (academics, students, and clinicians) or the Discovery Forum (industry partners). All AMP-PD data is available through https://www.amp-pd.org/ and requires access approval. Data from the German clinical diagnostic database will be made available upon request (manu.sharma{at}uni-tuebingen.de).
